Effects of neflamapimod (p38α kinase inhibitor) on clinical progression in patients with dementia with Lewy bodies (DLB) without Alzheimer’s disease (AD) Co‐Pathology

Abstract

Background: RewinD‐LB phase 2b study (NCT05869669) was initiated to confirm phase 2a results in DLB in which neflamapimod demonstrated positive effects on multiple clinical endpoints, most prominently in patients without evidence of AD co‐pathology (assessed by plasma ptau181).

The paper